Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

被引：0
|
作者：
Fazio, Francesca [1 ]
Di Rocco, Alice [1 ]
Za, Tommaso [2 ]
Tomarchio, Valeria [3 ]
Rago, Angela [4 ]
Piciocchi, Alfonso [5 ]
di Toritto, Tommaso Caravita
Annibali, Ombretta [3 ]
De Stefano, Valerio [2 ]
Foa, Robin [1 ]
Martelli, Maurizio [1 ]
Petrucci, Maria Teresa [1 ]
机构：
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Azienda Osped Policlin Umberto 1, Hematol, Rome, Italy
[2] Catholic Univ, Sect Hematol, Dept Radiol & Hematol Sci, Fdn Policlin A Gemelli, Rome, Italy
[3] Univ Campus Bio Medico, Hematol Unit, Stem Cell Transplantat, Rome, Italy
[4] UOSD Ematol ASL Roma 1, Rome, Italy
[5] Italian Grp Adult Hematol Dis GIMEMA, Rome, Italy
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149547
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3755
引用
收藏
页码：3755 / +
页数：5
相关论文
共 50 条
  • [41] Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
    Thibaud, Santiago
    Mia, Babu
    Van Oekelen, Oliver
    Mouhieddine, Tarek H.
    Schaniel, Christoph
    Ghodke-Puranik, Yogita
    Aleman, Adolfo
    Upadhyaya, Bhaskar
    Lancman, Guido
    Lagana, Alessandro
    Richard, Shambavi
    Rossi, Adriana
    Chari, Ajai
    Sanchez, Larysa
    Rodriguez, Cesar
    Cho, Hearn J.
    Richter, Joshua
    Hoffman, Ronald
    Jagannath, Sundar
    Parekh, Samir
    BLOOD, 2022, 140
  • [42] Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
    Que, Yimei
    Xu, Menglei
    Xu, Yanjie
    Almeida, Varlene Daniela Fernandes
    Zhu, Li
    Wang, Zhiqiong
    Wang, Ying
    Liu, Xian
    Jiang, Lijun
    Wang, Di
    Li, Chunrui
    Zhou, Jianfeng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [43] High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma
    Zhang, Xian
    Wang, Lin
    Yang, Junfang
    Li, Jingjing
    Liu, Hongxing
    Li, Jianqiang
    Lu, Peihua
    BLOOD, 2023, 142
  • [44] Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
    Marumo, Yoshiaki
    Ri, Masaki
    Ebina, Toru
    Nakamura, Tomoyuki
    Sasaki, Hirokazu
    Kinoshita, Shiori
    Narita, Tomoko
    Suzuki, Tomotaka
    Sanda, Takaomi
    Nanri, Takanori
    Komatsu, Hirokazu
    Iida, Shinsuke
    BLOOD, 2024, 144 : 24116 - 24117
  • [45] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [46] CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
    Krejci, Martin
    Adam, Zdenek
    Krejci, Marta
    Pour, Ludek
    Sandecka, Viera
    Stork, Martin
    NEOPLASMA, 2022, 69 (05) : 1008 - 1018
  • [47] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
    Yao, Xin
    Zhu, Shigui
    Huang, Jiaqi
    Qu, Xiaoyan
    Zhu, Judy
    Wei, Yutian
    Lan, Liping
    Lv, Xiaoteng
    Wu, Junfeng
    Wang, Rirfei
    Yang, Dingzhu
    Zheng, Chengxiao
    Zhao, DiJun
    Fan, Lei
    Huang, Fei
    Lu, Hua
    Zhang, Chaocan
    Chen, Cheng
    Li, Yanfeng
    Ren, Jiaqiang
    Zhang, Li
    Humphries, Michael
    Li, Jianyong
    Yao, Yihong
    BLOOD, 2019, 134
  • [48] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
    Zhang, Hua
    Gao, Lei
    Liu, Li
    Wang, Jishi
    Wang, Sanbin
    Gao, Li
    Zhang, Cheng
    Liu, Yao
    Kong, Peiyan
    Liu, Jia
    He, Jiaping
    Han, Yu
    Shi, Hua
    He, Yan
    Ye, Xun
    Zhao, Yi
    Cao, Wei
    Shen, Lianjun
    Zhang, Xi
    BLOOD, 2019, 134
  • [49] Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    Davis, James A.
    Dima, Danai
    Ahmed, Nausheen
    DeJarnette, Shaun
    McGuirk, Joseph P.
    Khouri, Jack
    Valent, Jason
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [50] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Madduri, Deepu
    Pacaud, Lida
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
12345